Tesofensine: What Clinical Trials Reveal About This Weight Loss Compound

Tesofensine: What Clinical Trials Reveal About This Weight Loss Compound

Important: This article is for educational and informational purposes only. Tesofensine is not FDA-approved for any indication. Nothing here is medical advice. Talk to a qualified healthcare provider before making any changes to your health regimen.

In a 2008 randomized controlled trial published in The Lancet, tesofensine produced weight loss roughly twice that of any approved obesity drug at the time. That single finding put it on the radar of researchers, physicians, and eventually the broader weight-loss community, including the peptide research space.

But tesofensine is not a peptide. It never was. Understanding what it actually is, how it works, and where the research currently stands is critical before you draw any conclusions about it.

This guide covers the science, the trial data, the safety concerns, and the honest gaps in what we know.

---

Key Takeaways

• Tesofensine is not a peptide. It is a triple reuptake inhibitor that blocks the recycling of serotonin, norepinephrine, and dopamine in the brain.
• It was originally developed for Parkinson's disease and Alzheimer's disease. Weight loss was discovered as a side effect during those neurological trials.
• It is not FDA-approved for any indication, including obesity.
• A Phase II trial showed the 0.5 mg dose produced approximately 9.2% body weight loss over 24 weeks, roughly double the effect of drugs available at the time.
• The 1.0 mg dose produced even greater weight loss (10.6%) but also increased heart rate more significantly.
• Cardiovascular effects are a real concern. Elevated heart rate and blood pressure were observed in trial participants.
• Phase III trials are ongoing through Saniona, the Danish biotech company that holds the compound.
• It appears in peptide communities because research chemical vendors often sell it alongside actual peptides, not because it shares their biology.

---

What Is Tesofensine?

Tesofensine (NS2330) is a small-molecule drug developed by Neurosearch, a Danish pharmaceutical company. It belongs to a class of compounds called triple monoamine reuptake inhibitors.

That means it works by blocking the reabsorption (reuptake) of three key brain chemicals: serotonin, norepinephrine, and dopamine. When these neurotransmitters stay active in the synaptic space longer, they influence appetite, energy, mood, and motivation.

It is not a peptide. Peptides are short chains of amino acids. Tesofensine is a synthetic piperidine derivative with an entirely different molecular structure and mechanism. The confusion arises because it is commonly discussed in peptide research communities and sold by some research chemical vendors alongside actual peptides. But the biology is not the same.

---

The Origin Story: From Brain Disease to Weight Loss

Tesofensine was not developed as a weight loss drug. It was designed to treat neurological diseases, specifically Parkinson's disease and Alzheimer's disease.

The reasoning made sense. Both conditions involve disrupted dopamine and norepinephrine signaling. A triple reuptake inhibitor could theoretically support neurotransmitter function in patients experiencing neurodegeneration.

During the neurological trials, researchers noticed something unexpected: participants were losing significant body weight.

That observation shifted the entire research focus. The Parkinson's and Alzheimer's programs were deprioritized. The weight loss signal was too strong to ignore.

Neurosearch pivoted to obesity as the primary indication. The compound was licensed to Saniona, a Copenhagen-based biotech, which has been advancing it through Phase III trials.

This kind of origin story is not unusual in pharmacology. Many drugs find their most important application somewhere other than where they started. But it does mean the weight loss mechanism in tesofensine was not engineered. It was discovered by accident and then studied systematically.

---

How Tesofensine Works: The Mechanism

The weight loss effect appears to come from two directions working simultaneously.

First, appetite suppression. By keeping serotonin and norepinephrine elevated, tesofensine reduces hunger signaling. Research suggests it lowers the reward value of food, making eating less compelling rather than simply making you feel "full." This is meaningfully different from GLP-1 receptor agonists like semaglutide, which primarily slow gastric emptying and act on satiety hormones.

Second, increased energy expenditure. The dopamine component appears to increase metabolic activity. Research by Sjödin et al. (PMID: 20060172) investigated tesofensine's effects on appetite and energy expenditure specifically, finding effects on both sides of the energy balance equation.

The combination of reduced intake and increased output is theoretically powerful. Most approved weight loss drugs work primarily on one side. That two-vector effect is one reason the Phase II results drew significant attention.

It is also why the cardiovascular concerns exist. Elevated norepinephrine in particular raises heart rate and can affect blood pressure. That tradeoff (metabolic benefit vs. cardiovascular load) has been central to every serious analysis of the compound.

---

Phase II Trial Results: The Numbers That Matter

The landmark study is Astrup et al., published in The Lancet in 2008 (PMID: 18950853).

Study design: Randomized, double-blind, placebo-controlled trial. 203 obese patients with a BMI between 30-40 kg/m². Five Danish obesity centers. All participants followed an energy-restricted diet. The trial ran for 24 weeks.

Weight loss by dose:

Group	Mean Weight Loss
Placebo + diet	2.0%
Tesofensine 0.25 mg	4.5%
Tesofensine 0.5 mg	9.2%
Tesofensine 1.0 mg	10.6%

All tesofensine doses showed statistically significant weight loss compared to placebo (p<0.0001).

The 0.5 mg dose attracted the most attention because the researchers noted it "might have the potential to produce a weight loss twice that of currently approved drugs" while having a more tolerable side effect profile than the 1.0 mg dose.

To put the numbers in perspective: the weight loss drugs on the market at that time typically produced 3-5 kg of additional weight loss over placebo. At the 0.5 mg dose, tesofensine produced roughly 7.2 percentage points more than placebo on top of diet. For many participants, that translated to 8-12 kg of actual weight lost.

161 of 203 participants (79%) completed the full 24-week trial. That completion rate is reasonable for a weight loss drug study.

---

Cardiovascular Concerns: What the Trial Found

This section matters. The cardiovascular profile of tesofensine is the primary reason it has not moved faster through the regulatory process.

From the Astrup et al. trial:

• Heart rate: Increased by 7.4 beats per minute in the 0.5 mg group (p=0.0001). The 1.0 mg group showed larger increases.
• Blood pressure: No significant increases were observed at 0.25 mg or 0.5 mg doses. The 1.0 mg dose showed more concerning cardiovascular signals.

The expert commentary on the trial (Doggrell, 2009, PMID: 19548858) noted that tesofensine "increased blood pressure and heart rate" and that "it may increase psychiatric disorders." These concerns directly shaped the design requirements for Phase III.

Why does this matter? Elevated resting heart rate over time is associated with increased cardiovascular risk, particularly in already-obese patients who may have existing heart and blood pressure issues. The FDA's history with weight loss drugs that affect cardiovascular function is cautious. Sibutramine, which worked through a similar (though less potent) monoamine reuptake mechanism, was withdrawn from the market in 2010 after a large trial showed increased risk of serious cardiovascular events.

Tesofensine is not sibutramine. But the mechanism overlap means regulators and researchers are watching the cardiovascular data in Phase III very carefully.

We are not making a judgment about whether the risk-benefit profile is acceptable. That determination belongs to regulatory agencies and treating physicians. What we can say is: the cardiovascular signal is real, documented in the Phase II data, and a central part of any honest evaluation of this compound.

---

Most Common Side Effects Reported in Trials

Based on the Phase II trial data, the most frequently reported adverse events were:

• Dry mouth: the most common complaint across all doses
• Insomnia: particularly at higher doses
• Constipation and hard stools
• Nausea
• Diarrhea (less common)
• Elevated heart rate: dose-dependent
• Increased blood pressure: primarily at 1.0 mg
• Mood effects: the Doggrell analysis flagged potential psychiatric concerns

Side effects were generally dose-dependent. The 0.25 mg dose had the mildest profile; the 1.0 mg dose had the most significant side effect burden. The 0.5 mg dose is where researchers have focused most of the ongoing work, as it represents the apparent sweet spot between efficacy and tolerability, though "tolerable" is relative and individual variation matters.

None of this should be minimized. A compound that significantly raises your heart rate for months at a time is not something to take lightly, especially without physician supervision and regular monitoring.

---

Tesofensine Dosage: What Clinical Trials Used

Since tesofensine is not approved for human use, there are no official dosing guidelines. What exists is the clinical trial data.

The Phase II trial tested three doses:

• 0.25 mg per day: lowest dose, modest weight loss, most tolerable side effect profile
• 0.5 mg per day: moderate dose, approximately 9.2% weight loss over 24 weeks, considered the target dose for Phase III
• 1.0 mg per day: highest dose, greatest weight loss (~10.6%), but more significant cardiovascular effects

All doses in the trial were taken once daily. Duration was 24 weeks (about six months).

These figures are presented as educational context only, describing what researchers tested in a controlled clinical setting, not as a recommendation for use. Anyone considering this compound outside of a clinical trial should consult a physician. Period.

For comparison context on how this stacks up against other weight management approaches, see our guides to fat-burning peptides explained and peptides for belly fat.

---

Phase III Status: Where Things Stand Now

Saniona, the biotech company that holds the tesofensine license, has been running Phase III trials to evaluate the compound at scale with adequate cardiovascular monitoring.

Phase III is the critical gate. Phase II had 203 participants over 24 weeks. Phase III trials for obesity drugs typically require thousands of participants and multi-year follow-up, specifically to capture cardiovascular event rates. The FDA's experience with sibutramine means they now require cardiovascular outcome data before any similar drug gets approved.

As of our publication date, Saniona has not received FDA or EMA approval for tesofensine. The compound remains an investigational drug.

The trajectory has been slower than the 2008 excitement suggested it might be. That is not unusual. The gap between promising Phase II results and regulatory approval is long and failure-prone across all drug categories. Most compounds with good Phase II data still fail to reach approval.

Whether tesofensine eventually crosses that threshold depends on what the Phase III cardiovascular data shows.

---

Why Tesofensine Appears in Peptide Communities

This is a fair question. Tesofensine is not a peptide. Why do peptide forums, peptide vendors, and sites like ours discuss it?

A few reasons.

First, the research compound market overlaps. Vendors who supply actual research peptides (BPC-157, TB-500, GHK-Cu, etc.) often also source and sell other research chemicals, including compounds like tesofensine, MK-677, or cardarine, that are not peptides but circulate in the same communities.

Second, people pursuing body composition goals often research multiple compounds simultaneously. Someone reading about retatrutide or tirzepatide vs. semaglutide may also be researching tesofensine as part of their comparative analysis.

Third, the weight loss mechanism is genuinely interesting to the same audience that follows peptide research: people who want to understand the science behind fat loss, appetite regulation, and metabolic function.

That said, the biology is different, the regulatory status is different, and the risk profile is different. Conflating tesofensine with peptides leads to muddled thinking about how each category works and what the actual risks are.

---

Tesofensine vs. Other Weight Management Compounds

Since tesofensine often comes up in discussions alongside other weight loss compounds, here is a plain-language comparison.

Tesofensine vs. Semaglutide (Ozempic/Wegovy):

Semaglutide is a GLP-1 receptor agonist that is FDA-approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). Clinical trials showed approximately 14.9% body weight loss over 68 weeks at the approved 2.4 mg weekly dose. Semaglutide works primarily by mimicking a gut hormone that slows gastric emptying and promotes satiety. It does not significantly elevate heart rate. It has an established regulatory track record. Tesofensine works through an entirely different mechanism and has no approved status.

Tesofensine vs. Tirzepatide (Mounjaro/Zepbound):

Tirzepatide is a dual GIP/GLP-1 receptor agonist, FDA-approved for both diabetes and obesity. Phase III data showed up to 20.9% body weight loss in some participants. Like semaglutide, it acts on gut-based satiety pathways. It is currently the most effective approved obesity medication. For more detail, see our retatrutide vs. tirzepatide comparison.

Tesofensine vs. Retatrutide:

Retatrutide is a triple GIP/GLP-1/glucagon receptor agonist in Phase III trials. Early data suggests it may produce even greater weight loss than tirzepatide. Like tesofensine, it is not yet approved. Unlike tesofensine, retatrutide works through gut hormone pathways rather than central nervous system reuptake inhibition. See peptides for body recomposition for context on where retatrutide fits.

The comparison is not about which is "better." Each compound works differently, carries different risks, and has a different regulatory status. The relevant question for anyone working with a physician is which approach fits their specific health profile, goals, and medical history.

---

Legal Status

Tesofensine is not FDA-approved in the United States. It is not approved in the European Union or most other major jurisdictions.

It exists in a legal gray zone in many countries. In the US, it is not a scheduled controlled substance, but it is also not approved for human use. Some research chemical vendors sell it labeled "for research use only." A framing that technically sidesteps direct FDA enforcement but does not make the human use of unapproved drugs legal or medically sanctioned.

We are not going to moralize about what adults choose to research or discuss with their physicians. But we will be direct: using an unapproved drug with known cardiovascular effects, without physician supervision and monitoring, is a meaningful risk. The Phase II trial involved medical supervision, ECG monitoring, and regular follow-up. That context matters.

If tesofensine interests you, the appropriate channel is to work with a physician who has reviewed the available research and can monitor your cardiovascular markers.

---

FAQ

Is tesofensine a peptide?

No. Tesofensine is a synthetic triple monoamine reuptake inhibitor. It blocks the reabsorption of serotonin, norepinephrine, and dopamine. Peptides are chains of amino acids with entirely different biology. Tesofensine appears in peptide communities because it circulates in the same research compound market, not because it shares the same mechanism or structure.

How much weight loss does tesofensine cause?

The Phase II trial (Astrup et al., 2008) found that the 0.5 mg dose produced approximately 9.2% body weight loss over 24 weeks in obese participants following an energy-restricted diet. The 1.0 mg dose produced 10.6%. Results were dose-dependent and all statistically significant versus placebo. Individual results vary and these figures come from controlled clinical research, not real-world use.

Is tesofensine approved by the FDA?

No. Tesofensine has no FDA-approved indications. It is an investigational compound currently in Phase III trials for obesity, conducted by Saniona. It is not approved in the EU either. Using it outside a clinical trial involves meaningful regulatory and medical uncertainty.

What are the main side effects of tesofensine?

The most commonly reported side effects in clinical trials were dry mouth, insomnia, constipation, nausea, and diarrhea. Cardiovascular effects (specifically elevated heart rate and, at higher doses, elevated blood pressure) are the most significant safety concern. These effects were dose-dependent in the Phase II data.

How does tesofensine compare to semaglutide?

They work through completely different mechanisms. Semaglutide is an FDA-approved GLP-1 receptor agonist that mimics gut satiety hormones. Tesofensine is an unapproved triple reuptake inhibitor that acts centrally on dopamine, serotonin, and norepinephrine. Semaglutide produced about 14.9% body weight loss in its pivotal trials. Tesofensine produced 9.2% at the 0.5 mg dose in Phase II, though the trial durations and populations differed, making direct comparison difficult.

---

The Bottom Line

Tesofensine produced some of the most striking weight loss numbers seen in a Phase II obesity trial when the Astrup et al. data published in 2008. The mechanism (blocking the reuptake of three key neurotransmitters simultaneously) is genuinely different from GLP-1 agonists and produces effects on both appetite and energy expenditure.

The cardiovascular signal keeps it from being a straightforward story. Elevated heart rate and blood pressure effects at higher doses are real, documented concerns, and the regulatory environment for weight loss drugs affecting the cardiovascular system is appropriately cautious after sibutramine's withdrawal.

Phase III data from Saniona will determine whether the risk-benefit profile justifies approval. Until that data is published and reviewed by regulators, tesofensine remains an investigational compound, not a treatment option outside of clinical trials.

For people researching weight management options, the approved compounds (semaglutide, tirzepatide) have established safety records and regulatory oversight. For people working with physicians who are following the research compound space, understanding what tesofensine actually is (a triple reuptake inhibitor, not a peptide, with real cardiovascular considerations) matters for making informed decisions.

---

Medical Disclaimer: The information on this website is for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide protocol, medication, or supplement regimen. Individual results vary. The author shares personal experience and published research. This content does not constitute medical recommendations.

---

Sources

1. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients - Astrup et al. - The Lancet, 2008 (PMID: 18950853)
2. Tesofensine for obesity - an evaluation - Doggrell - Expert Opinion on Investigational Drugs, 2009 (PMID: 19548858)
3. Monoamine reuptake inhibitors for obesity treatment - Bello & Zahner - Expert Review of Endocrinology & Metabolism, 2009 (PMID: 19777399)
4. Tesofensine and energy expenditure - Sjödin et al. - 2010 (PMID: 20060172)
5. Saniona - Tesofensine clinical development - Corporate pipeline reference
6. Current and emerging pharmacotherapy for obesity - Srivastava & Apovian - Expert Opinion on Pharmacotherapy, 2018 (PMID: 29504049)